

VBC Release Highlights

September 8, 2023

Practice InsightsSM is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS) and Enhancing Oncology Model (EOM).

MIPS Quality Measures Dashboard

Promoting Interoperability Measure Specification Refinements

The dashboard has been updated to reflect scoring changes for the below measures:

Measure	Update
Provide Patient Access to Electronic Health Records	When submitting this measure at the end of the year, the maximum number of points received will now be 25 points, not 40 points.
Closing the Referral Loops by Sending Health Information	When submitting this measure at the end of the year, the maximum number of points received will now be 15 points, not 20 points.
Closing the Referral Loops by Receiving & Reconciling Health Information	When submitting this measure at the end of the year, the maximum number of points received will now be 15 points, not 20 points.

Quality Measures Technical Refinements

The dashboard has also been updated to reflect the below refinement(s) for:

Measure	Update	Practice Impact
<p>PIMSH 15: Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)</p>	<ul style="list-style-type: none"> • While the measure was coded as expected an issue was identified with how the measure was displaying patients in the Minimal category. This release addresses that issue. • Technical refinement to ensure the patient is attributed to the clinician with the qualifying E/M visit. • Cyclophosphamide was included up to ≥ 1500 but now will be included with dosage > 1500. • Technical refinement to better capture new or refilled prescription orders of an antiemetic within 89 days prior to cycle 1 day 1 of the therapy. • Medications on the Current Medications list will be captured when there is an active order on the medication list 90 days prior to cycle 1 day 1 of therapy. 	<p>Practices will notice an increase in the Numerator and Denominator.</p>
<p>PIMSH 16: Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center</p>	<ul style="list-style-type: none"> • While the measure was coded as expected an issue was identified with how the measure was displaying patients in the Minimal category. This release addresses that 	<p>Practices will notice an increase in the Numerator and Denominator.</p>

Measure	Update	Practice Impact
---------	--------	-----------------

- issue.
- Technical refinement to ensure the patient is attributed to the clinician with the qualifying E/M visit.
 - Technical refinement to better capture new or refilled prescription orders of an antiemetic within 89 days prior to cycle 1 day 1 of the therapy.
 - Medications on the Current Medications list will be captured when there is an active order on the medication list 90 days prior to cycle 1 day 1 of therapy.

VBC Navigation Summary Dashboard

We updated the VBC Navigation Summary dashboard to provide you with more accurate and comprehensive insights into VBC Care Plan information sourced from iKnowMedSM Generation 2. These updates aim to streamline your workflow and empower you with crucial hospice-related data.

Here's what you can expect from the newly added columns:

1. **Referral to Hospice:** This column will display the status of patients' referral to hospice care, offering a clear overview of whether patients have been referred.
2. **Referral to Hospice Date:** Gain deeper insights into the timing of hospice referrals with this date field.
3. **Enrolled in Hospice:** Keep track of whether patients are actively enrolled in hospice care.

-
4. **Enrolled in Hospice Date:** Understand the exact enrollment dates for patients in hospice care.

All this essential information will be seamlessly populated from the VBC Care Plan, ensuring that your dashboard remains up-to-date and accurate. These enhancements are designed to optimize your view of patients participating in quality payment programs.

Status of Dashboard Updates for 2023

CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2023 requirements. The measures listed below either have no 2023 update required or have been updated.

NOTE: Table continues on the next page.

Measure	Description
MIPS Quality Measures Dashboard	
#047	Advance Care Plan
#104	Adjuvant Hormonal Therapy for High-Risk or Very High-Risk Prostate Cancer
#130	Current Medications Documentation
#134	Preventive Care Screening: Screening for Depression and Follow-Up Plan
#143	Pain Intensity Quantified
#144	Pain Care Plan
#226	Tobacco Screening and Cessation
#236	Controlling High Blood Pressure
#374	Closing the Referral Loop
#451	RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
#452	Percentage of Adult Patients (aged 18 or older) with Metastatic Colorectal Cancer and RAS (KRAS & NRAS) Gene Mutation Spared Treatment with Anti-EGFR Monoclonal Antibodies
#457	Patients Admitted to Hospice for < 3 Days
PIMSH#1	Advance Care Planning in Stage 4 Disease
PIMSH#2	Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)

Measure	Description
PIMSH#4	Patient-Reported Pain Improvement
PIMSH#8	Mutation Testing for Lung Cancer
PIMSH#9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10	Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs
PIMSH#15	Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH#16	Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center